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Extranodal T/NK Lymphomas
Silvana Novelli
Abstract
Extranodal T/NK lymphomas comprise infrequent and highly aggressive entities 
such as extranodal NK/T-cell lymphoma nasal type, enteropathy-associated T-cell 
lymphoma, monomorphic epitheliotropic intestinal T-cell lymphoma, intestinal 
T-cell lymphoma NOS, and hepatosplenic T-cell lymphoma. Except for NK/T 
lymphoma nasal type, there is scarce evidence to support a specific therapeutic 
regimen in first line and relapse. As the only potentially curative therapy is allo-
geneic hematopoietic stem cell transplantation, it should be assessed in relapsing/
refractory NK/T lymphoma nasal type and in the first line after remission in the 
other extranodal NK/T lymphomas.
Keywords: extranodal lymphoma, NK/T-cell lymphoma, NK lymphoma, 
hepatosplenic
1. Introduction
In this chapter, the majority of extranodal T/NK lymphomas will be discussed 
proportionally to the amount of available evidence and its clinical relevance. The 2016 
WHO classification [1] includes the following entities: extranodal NK/T-cell lym-
phoma nasal type, enteropathy-associated T-cell lymphoma, monomorphic epithelio-
tropic intestinal T-cell lymphoma, intestinal T-cell lymphoma NOS, and hepatosplenic 
T-cell lymphoma. In general, these are very infrequent and aggressive lymphomas, 
being the most prevalent the extranodal NK/T-cell lymphoma, nasal type. The current 
classification separates enteropathy-associated T-cell lymphoma from monomorphic 
epitheliotropic intestinal T-cell lymphoma in two different entities; in this way, 
intestinal T-cell lymphoma NOS remains a category to place unclassifiable histologies. 
Recent advances in gene expression profiling have allowed identify genes and proteins 
with potential role in pathogenesis. Collaboration between different centers is showing 
promising results that will surely modify and improve current treatments and progno-
sis. It will also help to increase the evidence in the new classification categories.
2. Extranodal NK/T-cell lymphoma, nasal type (ENKL)
2.1 General features
Natural killer (NK) neoplasias are divided into extranodal NK/T, nasal type, and 
NK aggressive leukemia. The “nasal type” distinction is explained because there is a 
predominant affection of nasal zone, nasopharynx, and upper respiratory airways 
(60–90% of cases). The “extra-nasal” type also exists but is infrequent; it affects 
non-nasal areas such as the skin, testicles, intestines, and muscles [2].
Peripheral T-cell Lymphomas
2
Several works have tried to identify biologic differences between both clinical 
manifestations but it has not been possible. The “extra-nasal” variant has a worse 
outcome; patients frequently present with B symptoms, advanced stages, hemo-
phagocytosis, and cytopenias.
Unlike Asia and Latin America, ENKL is infrequent in our media representing 
approximately 2% of non-Hodgkin lymphomas [3].
2.2 Etiology
Epstein-Barr virus (EBV) is an important feature of ENKL [4]. More than 
90% of reported cases were positive for EBNA-1 and EBER-1. EBV is present in an 
episomal form not integrated into the host DNA, with type II latency [5, 6].
2.3 Diagnosis
At the morphological level, angiocentric and angio-invasive infiltrates composed 
of small-medium-sized atypical lymphocytes with irregular nuclei and immunoblasts 
are evident. There is a variable infiltration of plasma cells and, to a lesser extent, of 
eosinophils and histiocytes. The presence of extensive necrosis is frequent.
By immunohistochemistry, the tumor NK cells can have two lines of origin:
NK line (65–75% of cases): CD2 (+), CD3-ε (+) cytoplasmic, CD56 (+/−),  
CD94 (+), cytotoxic markers (TIA, GZM-B, perforin) (+), and TCR-β (BF1) (−).
True T-line (25–35% of cases): CD2 (+), CD3-ε (+), CD5 (+), CD8 (+/−),  
TCR-β (BF1) (+), CD56 (−/+), and cytotoxic markers (+).
EBV is detected in almost all cases by in situ hybridization (EBER) and by 
Southern blot. The latent EBV membrane protein has a variable expression, so it is 
not advisable to detect the virus [7].
Early chromosomal examinations recognized del(6)(q21q25) as a repetitive 
chromosomal anomaly in ENKL. In view of investigations of 6q, including gene 
expression profiling (GEP), PRDM1, FOXO3, and PTPRK were recognized as 
putative tumor suppressor genes. A high expression of genes of cytotoxic molecules 
such as granzyme H and deregulation of the NF-κB, AKT, and JAK-STAT3 pathways 
were also present in ENKL. Half of the patients have mutations in FAS and <50% in 
TP53. DDX3X and BCL6 are also mutated; the former was more frequently mutated 
in men and was associated with poor survival [8].
2.4 Staging and prognosis
Because the prognosis is different between the “nasal” and the “extranasal” vari-
ants, techniques to detect occult disease become clinically important.
It is advisable to use PET/CT since it has shown greater sensitivity. In those cases 
where there is evidence of involvement of the central nervous system, it is necessary to 
consider complementing the study with magnetic resonance imaging (MRI) [9, 10].
Bone marrow biopsy is part of staging and cannot yet be replaced by the exten-
sive use of PET/CT in this entity [11].
The staging should be performed according to Ann Arbor since most clinical 
trials have established it that way. However, TNM staging is also widely used since 
it offers the advantage of better assessing tumor size and infiltration of adjacent 
organs and tissues of the localized stage [12].
The ENKL prognostic index includes both stage and other variables. This index 
is fundamental for decision-making [13].
The ENKL index punctuates the presence of “B” symptoms, Ann Arbor stage ≥III, 
LDH ≥1 × upper normal limit, and regional lymph nodes (N1-N3, not M1) involvement 
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according to the TNM staging system. Every point increases the relative of death and 
impairs survival (see Table 1).
The viral quantification of EBV is useful to assess the tumor burden. Negative 
loads have a better prognosis than cases with low EBV load (<1000 copies/ml in 
plasma or <100 copies/mcg of mononuclear cell DNA) and that of high load. It is 
also useful to monitor the response to therapy. Therefore, it should be done when-
ever possible [14, 15].
2.5 Treatment
The treatment is planned according to the stage and the risk.
In patients with stages I–II and low risk, radiotherapy (≥54 Gy) is the best option. 
It has not been observed that adding chemotherapy improves the prognosis [2, 16, 17].
If we focus on cases with stages I–II, but intermediate risk and high risk, it has been 
shown that the best option is the combination of chemotherapy and radiotherapy.
In the JCOG0211 study, radiotherapy (50 Gy) and three cycles of dexametha-
sone, etoposide, ifosfamide, and carboplatin (DeVIC) were administered. The 
overall survival (OS) at 2 years was 78% (95% CI, 57–89%). It was compared with a 
historical control of patients treated only with radiotherapy (OS 45%). The overall 
response rate was 81% (77% complete response, CR) [18].
Another study showed similar results. Radiotherapy (40–52.8 Gy) and cisplatin 
30 mg/m2 weekly followed by three cycles of VIPD (etoposide 100 mg/m2 days 1–3, 
ifosfamide 1200 mg/m2 days 1–3, cisplatin 33 mg/m2 days 1–3, and dexamethasone 
40 mg days 1–4). The progression-free survival (PFS) and the OS estimated at 
3 years were 85 and 86%, respectively [19].
ENKL is associated with a high expression of P glycoprotein that confers 
resistance to most anthracycline-based regimens. For this reason, non-dependent 
glycoprotein-P schemes have been designed.
The regimens that have demonstrated greater efficacy are based on 
L-asparaginase. However, they are associated with a high toxicity.
Also for stages IE–IIE (all risk groups), the DICE–L-asparaginase chemotherapy 
with radiotherapy (45 Gy) after four cycles vs. radiotherapy alone has been tested 
The CR rate was higher for patients in the sequential radiotherapy group (90.9%) 
than in the radiotherapy group (77.8%; p = 0.124). PFS and OS at 5 years after 
diagnosis were significantly higher for patients in the chemo-radiotherapy group 
(PFS: 89%; OS: 82%) than in the radiotherapy group (PFS: 49%, p < 0.001; OS: 
49%, p < 0.001) [20].
In advanced stages, the treatment must take into account the functional status of 
the patient.
If the patient’s general condition allows it (ECOG 0–2) and the patient is a candidate 
for an autologous hematopoietic stem cell transplant (ASCT), the first-line therapy 
will be the SMILE scheme followed by TASP (dexamethasone: 40 mg EV or oral, days 
Risk group Number of factors % 5-year OS RR of death
Group 1 0 81 1
Group 2 1 64 1.8
Group 3 2 34 4.1
Group 4 3–4 7 13.6
OS, overall survival; RR, relative risk.
Table 1. 
Survival and relative risk of death.
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Figure 1. 
Proposed treatments for extranodal NK/T-cell lymphoma, nasal type NK/T. KPI, Korean prognostic index; 
RDT, radiotherapy; L-Asp, L-asparaginase; ASCT, autologous stem cell transplant; alloSCT, allogeneic stem 
cell transplant; R/R, relapsed/refractory.
2–4; methotrexate: 2000 mg/m2 EV, day 1; ifosfamide: 1500 mg/m2 EV, days 2–4; E. coli 
L-asparaginase: 6000 U/m2 EV, days 8, 10, 12, 14, 16, 18, and 20; etoposide: 100 mg/m2 
EV, days 2–4).
The overall response rate (ORR) and the complete responses after 2 cycles were 
79% (90% CI, 65–89%) and 45%, respectively. Approximately half of the patients 
received an ASCT.
However, in those in the first line, the ORR was higher (86%), with CR of 
69%. These responses were maintained in 90% of patients during follow-up. The 
OS at 1 year was 55% (95% CI, 38–69%). On the other hand, grade 4 neutropenia 
occurred in 92% of the cases [21, 22].
Another option for this high-risk group is the L-asparaginase, methotrexate, and 
dexamethasone (AspaMetDex) chemotherapy. In a phase 2 trial, it reported a CR 
rate of 61% after three cycles. Further results are needed to confirm the efficacy of 
this regimen [23].
In those patients with poor general condition and/or those who do not want to 
receive an ASCT, the management must be palliative or investigational since the 
prognosis is unfortunate.
However, there is evidence that the “sandwich” scheme of GELOX (gem-
citabine, oxaliplatin, and L-asparaginase) and radiotherapy after at least two 
cycles of GELOX offers good results and acceptable toxicities in IE–IIE stages. 
The ORR was 96.3%, with CR of 74.1%. The OS and PFS at 2 years were both 
86% [24, 25].
In relapse, if patients are tributary to treatment and have not received the SMILE 
scheme, this will become the second line based on the results described above. 
However, if the patient has been refractory to the SMILE scheme, the alternatives 
are also investigational and with scarce evidence.
There is a retrospective study with the GELOX scheme. The ORR was 40% 
(20% CR). Those who achieved CR (two received ASCT and maintenance with 
L-asparaginase) were disease free for 7 months [26].
Regarding ASCT and allogeneic stem cell transplantation (alloSCT), there is less 
evidence of its role in high risk and/or advanced stage ENKL.
There is a prospective study in the pre-L-asparaginase era which included 16 
ENKL cases. Nine cases received an ASCT in first or second CR and the remaining 
in progression. The OS at 2 years was 71.3% (first to second CR) and 25.8%,  
respectively [27].
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A registry study that includes 18 cases of patients who received an alloSCT dem-
onstrated a PFS and OS at 5 years of 51 and 57%, respectively. Therefore, it becomes 
an alternative in very selected patients [28] (Figure 1).
New therapies, but not approved yet, are showing promising results. The most 
important results are those results obtained from the use of check point inhibitors 
(nivolumab and pembrolizumab). ORR oscillated between 57 and 100% but phase 
II trials are missing to confirm these results [29–31].
3. Enteropathy-associated T-cell lymphoma (EATL)
3.1 General features
The EATL currently refers exclusively to previous type I EATL and is clearly 
associated with celiac disease (CD) and occurs more frequently in patients of 
Northern European origin. Dermatitis herpetiformis and hyposplenism may be 
associated. Patients who are diagnosed at a higher age of celiac disease have a higher 
risk of having an LTAE and proper management with a gluten-free diet effectively 
prevents its development [32, 33].
The most affected regions are the jejunum or ileum and are usually diagnosed 
after a resection for an acute abdomen. Patients have a rapid deterioration of their 
general condition despite strictly following the diet.
Refractory celiac disease (RCD) is the precursor lesion. It is defined by histologi-
cal changes associated with enteropathy in cases with strict diet for >12 months or 
severe and persistent symptoms that require a clinical intervention regardless of the 
duration of the strict diet. There is a sub-classification, RCD type I, if the intraepi-
thelial lymphocytes show a normal phenotype and constitute a polyclonal popula-
tion, and RCD type II, if the intraepithelial lymphocytes immunophenotype is 
aberrant and clonal products are detected on TCR gene rearrangement analysis [34].
Loss of heterozygosity at 9p21, involving CDKN2A/B locus, was detected in 
more than 50% of cases with EATL. Loss of 17p12-p13.2 (TP53) was reported in 
23%, but a high frequency of aberrant nuclear p53 expression (75%) suggested 
alternate means of deregulation of this tumor suppressor. Surprisingly, there are 
more new findings in terms of etiology in the monomorphic epitheliotropic intesti-
nal T-cell lymphoma, and this will be further revised.
3.2 Diagnosis
Endoscopic findings show one or multiple ulcerated intestinal masses or large 
exophytic masses. At the serological level, tissue anti-transglutaminase IgA and anti-
endomysial IgA are the most sensitive and specific tests. The typing of HLA-DQ in 
search of the alleles that predispose to CD (DQ2/DQ8) is part of the diagnosis [35].
Histologically, EATL is characterized by a non-monomorphic infiltrate of cells 
with CD3 (+), CD7 (+), CD103 (+), cytotoxic proteins (+) CD8 (−/+), TCR-β 
(+/−), CD4 (−), CD5 (−), CD56 (−), and CD30 focally (+) in a subset of cases. 
Adjacent intraepithelial lymphocytes also have an aberrant immunophenotype CD3 
(+), CD5 (−), CD8 (−), CD4 (−), and cytotoxic proteins (−).
At the cytogenetic level, gains of 1q and 5q are observed [36].
3.3 Staging and prognosis
Staging will be carried out with the Lugano system [37] (see Table 2) Diagnostic 
tests include a CT scan, an endoscopic study, and a bone marrow biopsy. The index 
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that best defined prognosis of the EATL is the prognostic index used for peripheral 
T lymphomas (IPI) [38].
3.4 Treatment
Because at the time of diagnosis the patient is usually in advanced stages and 
have a poor nutritional status, therapeutic success is scarce.
Surgery plays an important role in reducing tumor burden and decreasing 
perforations or bleeding during chemotherapy, but on the other hand, it can delay 
the onset of chemotherapy [39, 40].
The most used chemotherapy is the CHOP scheme. Only 50% of patients will 
be able to receive chemotherapy, and of these, only 50% will complete it. Of those 
who complete chemotherapy, 35–40% will achieve a complete remission of the 
lymphoma. The median duration of the response is approximately 6 months [41].
In those patients who are candidates to receive an ASCT in first remission, it is 
advisable to do it following the EBMT recommendations [42]. In the most recent study 
of the EBMT registry, 31 cases of patients with EATL were identified. With a median of 
46 months of follow-up, the SLP and the OS at 4 years were 54–59%, respectively [43].
Refractory patients are unlikely to benefit from a second line of chemotherapy. 
No superiority of any regimen has been demonstrated, so it is advisable to follow 
usual schemes in the center of origin [44].
4. Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL)
4.1 General features
The MEITL is the intestinal lymphoma that was previously classified as EATL 
type II. Because it has shown both clinical and biological differences with the EATL, 
it has been constituted as a new entity. It is not associated with celiac disease and 
has a greater incidence in Asian and Hispanic populations. Its frequency is 10–15% 
of intestinal T lymphomas.
Stage I Tumor confined to GI tract. Single primary site or multiple, non-
contiguous lesions.
Stage II Tumor extending into abdomen 
from primary GI site.
Nodal involvement
II1 local (paragastric in cases 
of gastric lymphoma and 
para-intestinal for intestinal 
lymphoma)
II2 distant (mesenteric in the 
case of an intestinal primary, 
otherwise; para-aortic para-
caval, pelvic, inguinal).
Stage IIE Penetration of serosa to involve adjacent organs or tissues 
(enumerate actual site of involvement, e.g., IIEpancreas, IIElarge 
intestine).
Where there is both nodal involvement and penetration to involve adjacent organs, stage should be denoted 
using both a subscript (1 or 2) and E, e.g., II1Epancreas.
Stage IV Disseminated extranodal involvement, or, a GI tract lesion with 
supra-diaphragmatic nodal involvement.
Table 2. 
Lugano staging system for gastrointestinal tract lymphoma.
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4.2 Diagnosis
The tumor is composed of a monomorphic infiltrate. The immunophenotype is 
CD3 (+), CD8 (+), CD56 (+), TCR-β (+), CD4 (−).
In exceptional cases, TCR-γδ (+) has been demonstrated. Adjacent intraepithe-
lial lymphocytes show an aberrant immunophenotype.
One way to differentiate it from other NK/T and EATL lymphomas is the posi-
tivity for the megakaryocyte-associated tyrosine kinase (MATK).
At the cytogenetic level, gains are observed in MYC (locus 8q24) [45].
The staging and prognosis will be carried out in the same way as for the EATL.
4.3 Treatment
There are no clinical trials that allow favoring one treatment regimen over 
another. However, there are retrospective studies where it is confirmed that the 
anthracycline regimens are the most used (72%). The overall response rate was 46% 
(CR 38%)[46].
Recently, the potential effect of pralatrexate has been reported in a relapsed 
patient after anthracycline containing regimen [47] and also the addition of PEG-
asparaginase to EPOCH regimen in a non-responding patient [48].
The recommendations to perform an autologous transplant in the first remission 
are the same as in the EATL following the EBMT experience and recommendation 
for T-cell neoplasia [42, 49].
5. Hepatosplenic T-cell lymphoma (HSTL)
5.1 General features
HSTL is a rare entity. It represents 1% of non-Hodgkin’s lymphoma and 3% of 
T-lymphoma. Survival at 5 years does not exceed 7%; therefore, it has a poor clinical 
prognosis [50].
The etiology is unclear; however, it is postulated that chronic stimulation in 
patients with immune deficiencies or immune dysregulation could be important. 
Twenty percent of cases occur in young patients with some degree of immunosup-
pression (posttransplant, under treatment of leukemia). It has also been associated 
with the use of TNFα and immunomodulators in patients with inflammatory bowel 
disease and arthritis [51, 52].
5.2 Diagnosis
It is characterized by the proliferation of malignant T cells of medium size in 
the hepatic sinusoids, in the red pulp of the spleen, and in the bone marrow. The 
immunophenotype of the tumor cell is CD4−, CD8− (CD8+ alginates), CD2+, 
CD3+, CD42, CD52, CD76, and CD82. The TCR is usually gamma-delta, although 
there are cases described alpha-beta. The detected cytogenetic anomalies include 
isochromosome 7q and trisomy 8 [53].
Recently, the genetic basis of HSTL was described using whole exome sequenc-
ing. Some chromatin-modifying genes (INO80, SETD2, and ARID1B) were com-
monly mutated in HSTL; there are frequent mutations in STAT5B (31%), STAT3 
(9%), and PIK3CD (9%) and less frequent events in EZH2, KRAS, and TP53. SETD2 
that works as a tumor suppressor gene was the most frequently silenced gene [54]. To 
further determine the pathogenesis, a multicenter group performed an array-based 
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DNA methylation profiling and identified eight genes consistently hypermethylated 
(BCL11B, CXCR6, CD5, GIMAP7, SEPT9, LTA, UBAC2, and UXS1) and four genes 
hypomethylated (ADARB1, NR1H3, NFIC, and ST3GAL3) [55].
5.3 Staging and prognosis
Staging is performed with the Ann Arbor system. A specific prognostic index for 
this lymphoma has not been described because of its low frequency.
5.4 Treatment
The most used treatments are CHOP and hyper-CVAD. The cases that respond 
can go directly to autologous or allogeneic transplant.
Other regimens described in a retrospective study (n = 14) have been ICE 
and IVAC in first line and also in rescue after CHOP. While it is a small series, the 
authors emphasize that the use of more intensive schemes followed by precursor 
transplant hematopoietic agents could improve efficacy data [56].
The relapse-free time and the OS post alloSCT are 18 and 68 months, respec-
tively. The relapse-free time and the OS at 3 years are 42 and 56%, respectively. In 
this way, it is the only treatment that offers some probability of healing [57].
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